Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

NCT04037462 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT04037462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04037462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy
Lead sponsor
VA Office of Research and Development
Phase
Phase 1/2
Overall status
Terminated
Start date
July 7, 2021
Completion date
February 23, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, non-small cell lung cancer